Guideline-directed management of COVID-19: Do's and Don'ts
- PMID: 33766949
- PMCID: PMC7996221
- DOI: 10.1183/13993003.00753-2021
Guideline-directed management of COVID-19: Do's and Don'ts
Abstract
This editorial summarises the highlights of the European Respiratory Society COVID-19 treatment guideline
Conflict of interest statement
Conflict of interest: M. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation and Canadian Institute for Health Research, grants personal fees for advisory board work and other (site PI in industry-sponsored clinical trials) from Boehringer Ingelheim and Roche, grants and personal fees for advisory board work from Prometic and Pieris, other (chief editor allowance) from European Respiratory Journal, personal fees for advisory board work from Third Pole, MitoImmune, Abbvie, DevPro Biopharma, Horizon, Algernon and CSL Behring, outside the submitted work. Conflict of interest: A.T. Dinh-Xuan reports personal fees for lectures from Chiesi, Circassia and GSK, outside the submitted work. Conflict of interest: L. Brochard reports grants from Medtronic Covidien and Draeger, non-financial support from Fisher Paykel, Philips and Sentec, other (patent) from General Electric, outside the submitted work.
Comment on
-
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.Eur Respir J. 2021 Apr 15;57(4):2100048. doi: 10.1183/13993003.00048-2021. Print 2021 Apr. Eur Respir J. 2021. PMID: 33692120 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical